Cystic Acne: Increasing Prevalence of Acne is Expected to Boost The Topical Medications Treatment Market Growth During The Forecast Period 2022-2030

Pune, India, January 2022 /MRFR Press Release/- Market Research Future has a half cooked research report on the global cystic market.

Market Highlights

Cystic acne is majorly treated with topical medications, drainage & extraction procedure, and laser therapy, and microdermabrasion. Increasing awareness and prevalence of population affected by acne are boosting the demand for a laser treatment that has driven the growth of laser devices and medications for the cystic Acne. The cystic acne market has been a growing market and it has been expected that the market is likely to touch high growth figures.

According to The National Center for Biotechnology Information, in 2015, around 9.4% of the global population is affected by acne and making it the 8th most prevalent disease worldwide. Acne often causes significant physical and psychological problems such as permanent scarring, poor self-image, depression, and anxiety.

The market is expected to flourish in developing regions of Asia Pacific owing to the rising patient population with cystic acne. Increasing prevalence of cystic acne, rising demand for better treatment, increasing investment in the biotechnology and pharmaceutical industries for research and development are driving the growth of the market. Moreover, increasing government support for research & development, changing lifestyle, and rapidly developing technology are expected to fuel the market growth during the forecast period. However, lack of effective treatment in the market may hinder the market growth during the forecast period.

Regional Analysis

The Americas dominate the global cystic acne market owing to the presence of a huge patient population suffering from a skin condition, high health care spending, and increasing government support for research & development. According to American Academy of Dermatology, acne is affecting around 50 million Americans annually and around 20 million American have acne badly enough to cause scars.

Europe holds the second largest share of the global cystic acne market as a result of increasing focus of various government agencies on the treatment of diseases. Moreover, the growing public awareness about cystic acne is likely to boost the European market.

The Asia Pacific is the fastest growing market across the globe. Moreover, rapidly developing the economy, increasing healthcare expenditure, and the government’s initiatives for research & development are projected to drive the market in China and India.

The Middle East and Africa hold the least share of the global market due to limited availability of medical facilities.

Explore In-depth Details: Cystic Acne Market Research Report

Segmentation

The global cystic acne market is segmented on the basis of causes, long-term effects, treatment type and end user. On the basis of the causes, it is segmented into hormonal imbalances, occlusive skin products, drugs/chemical side effects, and others. On the basis of the long-term effects, it is segmented into ice pick scars, larger pits on the skin, shallow depressions, hypertrophic scarring, and others. On the basis of the treatment type, it is segmented into topical medications, drainage & extraction procedure, laser therapy, microdermabrasion, and others. On the basis of the end user, it is segmented into hospitals, clinics, research laboratories, and others.

Key Players

Some of the key players in this market are GlaxoSmithKline plc (U.K), Pfizer Inc. (U.S.), Abbott Laboratories (U.S.), Hexal AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Alma Lasers Inc. (Israel), Bristol-Myers Squibb Company (U.S.), GE Healthcare (U.K), National Biological Corp. (U.S.), Herbert Waldmann GmbH & Co. KG (Germany), Sylvan Company (U.S.) and DUSA Pharmaceuticals Inc. (U.S.).